Has Ilja Hulinsky, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,605,690 in general payments to Ilja Hulinsky, MD across 864 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ilja Hulinsky, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ilja Hulinsky, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ilja Hulinsky, MD

Endocrinology, Diabetes & Metabolism · Bridgeport, CTNPI 1134134018

Payments from drug & device makers

$1,605,690in general payments, 2019–2025

Across 864 payments — averaging $1858.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$976K
Modernatx, Inc.$263K
Pfizer$110K
Corcept Therapeutics$97K
Xeris Pharmaceuticals, Inc.$81K
Eli Lilly$39K
plus $39K from 35 others

$148in research payments, 2019–2025

Across 1 payment — averaging $147.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$148

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	96	$976,395
Modernatx, Inc.	63	$263,190
Pfizer	20	$109,829
Corcept Therapeutics	180	$96,891
Xeris Pharmaceuticals, Inc.	153	$81,377
Eli Lilly	9	$39,346
AstraZeneca(2 entities)	9	$32,368
Lilly USA, LLC	82	$1,399
Novo Nordisk	98	$1,296
Merck	23	$588
Sanofi-aventis U.S. LLC	18	$518
Amgen(2 entities)	22	$510
Bayer	10	$288
Amarin Pharma, Inc.	11	$170
Ascendis Pharma Endocrinology Inc	7	$167
Radius Health, Inc.	3	$161
Insulet Corporation	8	$136
Boehringer Ingelheim	8	$125
Neurocrine Biosciences, Inc.	1	$125
Novartis	8	$125
Ascensia Diabetes Care US Inc.	3	$80
Cequr Corporation	2	$59
Amneal Pharmaceuticals LLC	2	$51
IBSA Pharma Inc.	3	$50
Johnson & Johnson	3	$48
Arbor Pharmaceuticals, Inc.	3	$44
Valeritas, Inc.	2	$41
GSK	2	$41
Mannkind Corporation	2	$38
Vertical Pharmaceuticals, LLC	2	$35
Recordati_rare_diseases_inc.	1	$25
Kyowa Kirin, Inc.	1	$25
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$24
Azurity Pharmaceuticals, Inc.	1	$23
Intra-sana Laboratories	1	$20
Tolmar Pharmaceuticals, Inc.	1	$17
Ultragenyx Pharmaceutical Inc.	1	$15
Aytu Biopharma, Inc.	1	$14
Genentech USA, Inc.	1	$13
Tandem Diabetes Care, Inc.	1	$12
Teva Pharmaceuticals USA, Inc.	1	$12

How this compares

$1,605,690 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024

$34,387

Medicare patients

Services billed

296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Bridgeport

Ania JastreboffNew Haven$2.2M
Gerald ShulmanNew Haven$1M
Karl InsognaNew Haven$903K
Clemens BergwitzNew Haven$735K
Egils BogdanovicsTorrington$608K
Robert ObersteinHartford$516K
Fadi Al-KhayerStorrs$489K
Silvio InzucchiNew Haven$461K
Francis WilsonNew Haven$415K
Philip GoldbergNew Haven$324K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →